Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Item 9 Labs Corp. (INLB)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.7700-0.0200 (-2.53%)
At close: 03:31PM EDT
Advertisement
Full screen
Loading interactive chart...
  • PR Newswire

    Item 9 Labs Corp. Nears Completion of Cannabis Cultivation and Lab Facility in Pahrump, Nevada

    Item 9 Labs Corp. (OTCQX: INLB) (the "Company")—a vertically integrated cannabis dispensary franchisor and operator that produces premium, award-winning products—is pleased to announce today that its new 20,000 square-foot, state-of-the-art cultivation and lab facility in Pahrump, N.V. (the "Nevada Facility") is nearing completion and expected to be fully operational by end of 2022.

  • MarketWatch

    U.S. cannabis company Item 9 Labs buys Canada's Sessions Cannabis

    Phoenix-based Item 9 Labs Corp. said Wednesday it'll pay an undisclosed sum to acquire Canada's Sessions Cannabis, which generates about C$70 million in annual sales with 43 stores in Ontario. Item 9 Labs Corp. CEO Andrew Bowden said the acquisition "fast-tracks our entry into the Canadian market." Shares of Item 9 Labs are down 9.9% in 2022, compared to a drop of 46% by the AdvisorShares Pure US Cannabis ETF .

  • PR Newswire

    Item 9 Labs Corp. Signs Definitive Agreement to Acquire Sessions Cannabis, One of Canada's Largest Cannabis Retail Franchisors

    Item 9 Labs Corp. (OTCQX: INLB) (the "Company") — a vertically integrated cannabis dispensary franchisor and operator that produces premium, award-winning products — announced today that it has signed a definitive agreement to acquire Sessions Cannabis ("Sessions"), one of Canada's largest cannabis retail franchisors.

Advertisement
Advertisement